ConSynance Initiates Toxicology Studies on CSTI-300 for Irritable Bowel Syndrome

RENSSELAER, N.Y.--()--ConSynance Therapeutics, Inc. announced today that it has initiated a series of toxicology studies for CSTI-300, its drug candidate for the treatment of irritable bowel syndrome with diarrhea (IBS-D). Successful completion and regulatory filings should allow the planned clinical studies to proceed immediately.

“We are delighted to launch these toxicology studies to enable clinical studies on CSTI-300”

IBS is a bowel disorder that is often associated with severe abdominal pain. It is estimated that 10-12% of all adults are affected resulting in $25 billion of annual economic burden. There is currently no adequate treatment for IBS-D. Drugs targeting a serotonin receptor have been the most clinically studied for IBS-D. While there is evidence of strong clinical efficacy, existing drugs have unacceptable adverse effects such as severe constipation and a low incidence of ischemic colitis, which have significantly restricted their use.

To remedy these limitations, ConSynance's CSTI-300 targets the serotonin receptor (5-HT3) as a partial agonist, which reduces activation of the receptor by endogenous serotonin but does not completely block receptor activity. Orally dosed CSTI-300 has displayed high levels of efficacy in translational preclinical models of IBS-D and excellent pharmaceutical properties.

Concurrent with these toxicology studies, additional pharmacology models are being conducted to explore the potential of CSTI-300 to treat IBS with alternating constipation and diarrhea (IBS-M), an additional subtype of IBS for which there are no therapeutic options indicated.

"We are delighted to launch these toxicology studies to enable clinical studies on CSTI-300,” said Peter Guzzo, PhD, CEO of ConSynance. “We believe CSTI-300's novel mechanism of action has the potential to be a blockbuster drug for IBS patients.”

About ConSynance Therapeutics, Inc.

ConSynance Therapeutics is a clinical-stage drug development company based in Rensselaer, New York. The company’s pipeline includes innovative treatments for nonalcoholic steatohepatitis (NASH), the orphan disease Prader-Willi syndrome, and irritable bowel syndrome. ConSynance are collaborating with Chengdu SciMount Pharmatech Co., Ltd., a drug discovery company based in China, on the preclinical studies for the IBS project. ConSynance is seeking corporate partners to help accelerate the development of its programs to market. www.consynance.com

Contacts

ConSynance Therapeutics, Inc.
Shuang Liu, PhD, 518-275-0176
President
shuang@consynance.com

Recent Stories

  • View Press Release
    ConSynance Presents NASH Results
    April 25, 2018
    RENSSELAER, N.Y.--(EON: Enhanced Online News)--ConSynance Therapeutics Inc. announced today that Peter Guzzo, Ph.D., CEO, presented data on the company's Phase I nonalcoholic steatohepatitis (NASH)... more »
RSS feed for ConSynance Therapeutics, Inc.

Release Summary

ConSynance Therapeutics, Inc. announced that it has initiated GLP toxicology studies for CSTI-300, its drug candidate for the treatment of IBS.

ConSynance Therapeutics, Inc.